RecruitingRecruiting
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743 · Erasca, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1/2 Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors
About this study
This is a first-in-human, Phase 1/1b, open-label, multicenter clinical study of ERAS-0015 as a monotherapy and in combination with other cancer therapies. The study will commence with dose optimization of ERAS-0015 monotherapy, followed by dose optimization of ERAS-0015 in combination with other cancer therapies.
Eligibility criteria
Inclusion Criteria:
* Age ≥ 18 years
* Willing and able to give written informed consent
* Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts.
* There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort.
* Able to swallow oral medication
* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
* Adequate cardiovascular, hematological, liver, and renal function
* Willing to comply with all protocol-required visits, assessments, and procedures
Exclusion Criteria:
* Previous treatment with a RAS inhibitor
* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015
* Received prior palliative radiation within 14 days of Cycle 1, Day 1
* Have primary central nervous system (CNS) tumors
* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Study design
Enrollment target: 600 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-06-05
Estimated completion: 2028-12-01
Last updated: 2026-11-16
Interventions
Drug: ERAS-0015Drug: ERAS-0015 in combination
Primary outcomes
- • Dose Limiting Toxicities (DLT) (Study Day 1 up to Day 21)
- • Maximum tolerated dose (MTD) (Study Day 1 up to Day 21)
- • Recommended dose for expansion (RDE) (Study Day 1 up to Day 21)
Sponsor
Erasca, Inc. · industry
With: Merck Sharp & Dohme LLC
Contacts & investigators
ContactErasca Clinical Team Team · contact · clinicaltrials@erasca.com · +1-858-465-6511
ContactLes Brail, Study Director, PhD · contact
InvestigatorGerri Lee · study_director, Erasca, Inc.
All locations (14)
Providence Medical GroupRecruiting
Santa Rosa, California, United States
University of ColoradoRecruiting
Aurora, Colorado, United States
Florida Cancer SpecalistsRecruiting
Sarasota, Florida, United States
Moffitt Cancer CenterRecruiting
Tampa, Florida, United States
Emory UniversityRecruiting
Atlanta, Georgia, United States
Dana Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
Massachusetts General Hospital (MG)Recruiting
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
The University of Texas MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
University of Texas at TylerRecruiting
Tyler, Texas, United States
NEXT VirginiaRecruiting
Fairfax, Virginia, United States
The Princess Margaret Cancer CenterRecruiting
Toronto, Ontario, Canada
Inje University Haeundae Paik Hospital Clinical Trial CenterRecruiting
Haeundae, Busan, South Korea
Seoul St. Mary's Hospital Clinical Trial CenterRecruiting
Seoul, South Korea